The compound and the prescription product
Elamipretide, also called SS-31 in research, is a mitochondria-targeting tetrapeptide. Its prescription formulation is Forzinity. The label describes binding to cardiolipin at the inner mitochondrial membrane. This biological target does not by itself demonstrate a benefit for every condition involving fatigue. [source]
Treat the research name and a verified prescription product as separate questions. A vial labeled “SS-31” online should not be assumed to have the identity, quality or clinical evidence of Forzinity.
What FDA approved
On September 19, 2025, FDA granted accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. Approval relied on knee-extensor strength as an intermediate endpoint reasonably likely to predict benefit; a confirmatory trial is required. It is not a general fatigue or longevity approval. [source]
This distinction is central to reading the evidence: approval is for a defined condition and product. It does not establish that a proposed off-label use will work, or that another preparation is equivalent.
Clinical evidence: read both positive and negative results
Barth syndrome: small controlled trial and extension
The study enrolled 12 males aged 12 years or older. It included a randomized, blinded comparison and a long open-label extension; ten entered the extension and eight remained through week 168.
How to read it: A rare-disease study can be small for practical reasons, but the sample and attrition still constrain interpretation. Open-label follow-up lacks the same protection against expectation and time-related changes as a concurrent blinded control. [source]
Which outcomes supported the approval?
In the randomized Barth trial, elamipretide was not superior to placebo on walking distance or fatigue. Knee-extensor strength increases were observed in the extension, not during the randomized phase.
How to read it: The accelerated approval is narrower than claiming that every symptom improved in a successful placebo-controlled trial. Confirmation of patient benefit remains important. [source] [source]
Primary mitochondrial myopathy: MMPOWER-3
Participants were randomized equally to subcutaneous elamipretide or placebo. The main walking-distance and fatigue endpoints were not met. The walking-distance difference was −3.2 metres (95% confidence interval −18.7 to 12.3; p=0.69).
How to read it: This trial did not establish benefit for the studied myopathy population. It neither cancels the separate Barth indication nor supports extrapolation to nonspecific tiredness, long COVID or athletic performance. [source]
International scope and study sponsorship
MMPOWER-3 involved Canada, Denmark, England, Germany, Hungary, Italy and the United States, with industry sponsorship and investigator disclosures reported in the paper.
How to read it: International recruitment broadens participation but does not turn a negative primary result into a positive one. Read funding, prespecified endpoints and participant characteristics together. [source]
Safety and clinical oversight
Forzinity commonly causes injection-site reactions. Serious hypersensitivity has been reported. The label includes renal-impairment precautions, limited data in some populations and a benzyl-alcohol warning for neonates. These points require professional assessment; they are not a complete safety checklist. [source]
A clinician should assess the diagnosis and expected benefit, and a pharmacist should review the actual formulation, current labeling and other medicines. Study monitoring is context-dependent; a generic “mitochondrial support” label cannot define appropriate care.
What a responsible protocol discussion includes
For approved treatment, the current prescribing information and specialist judgment determine care. For research, the protocol defines eligibility, comparison treatment, duration, endpoints and safety follow-up. These are different contexts.
This article does not create a general SS-31 cycle, combine it with MOTS-c or other peptides, or translate a clinical-trial regimen into self-treatment. No such combination was validated by the studies summarized here. If a proposed use is outside the approved indication, ask what direct evidence supports that particular condition.
Questions to take to a licensed clinician
- Does my confirmed diagnosis match the population studied?
- Is the proposed use within the Forzinity indication or outside it?
- What patient-important outcome would count as benefit?
- How do kidney function, hypersensitivity history and other medicines affect suitability?
- Which product is being considered, and what establishes its quality?
Sources & review scope
This is a focused, selected-source review, not a systematic review or a complete adverse-event inventory. Regulatory sources are dated snapshots. Publication in a journal or indexing in PubMed does not mean FDA endorsement.
- Forzinity prescribing information — DailyMed
Official labeling; indication, safety and clinical studies.
- FDA accelerated-approval announcement (September 19, 2025)
Approval basis and required confirmatory study.
- FDA Drug Trials Snapshot: Forzinity
Trial participants, design and outcomes.
- Karaa and colleagues. MMPOWER-3 (2023)
Randomized phase 3 trial. DOI: 10.1212/WNL.0000000000207402.
- MMPOWER-3 — full publication
Methods, international sites, funding and disclosures.
Edition 1 adds the initial evidence summary, limitations, safety context and discussion questions. No independent clinical sign-off has been recorded.